Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema

BACKGROUND: The BEVORDEX trial compared outcomes of eyes with diabetic macular oedema (DMO) randomised to receive either intravitreal dexamethasone (DEX-) implant or bevacizumab over 2 years. We assessed long-term efficacy and safety outcomes 5 years from enrolment. METHODS: Patients received standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornish, Elisa E, Teo, Kelvin YC, Gillies, Mark C, Lim, Lyndell L, Nguyen, Vuong, Wickremasinghe, Sanjeewa, Mehta, Hemal, McAllister, Ian L, Fraser-Bell, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763198/
https://www.ncbi.nlm.nih.gov/pubmed/34340975
http://dx.doi.org/10.1136/bjophthalmol-2021-319839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763198/
https://www.ncbi.nlm.nih.gov/pubmed/34340975
http://dx.doi.org/10.1136/bjophthalmol-2021-319839

Ejemplares similares